On November 18, 2021 Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), the German-American cancer molecular diagnostics company, reported that the Supervisory Board appointed Dr. Andrew Lukowiak as President and Chief Scientific Officer with effect from December 1, 2021 (Press release, Epigenomics, NOV 18, 2021, View Source [SID1234595767]). Dr. Lukowiak, who has held senior management positions in the U.S. molecular diagnostics industry, will become a member of the Executive Board of Epigenomics and oversee Research and Development and Operations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Lukowiak (49) has over 20 years of management experience in the molecular diagnostics and life sciences industries. Prior to joining Epigenomics, Andrew served as CEO and Board Member for Millennium Health, a leading specialty toxicology laboratory. Dr. Lukowiak was also Chief Operating Officer of AltheaDx Inc., where he led the development, validation and launch of multiple Real-Time PCR tests for a broad array of disease states. Additionally, he was a senior R&D executive at GenMark Diagnostics and Hologic, where he was responsible for both PMA and 510(k) cleared products including the support and automation of an HPV test for cervical cancer. Dr. Lukowiak earned his doctorate in Genetics from the University of Georgia and his Bachelor of Science in Biology from Pennsylvania State University.
Heino von Prondzynski, Chairman of the Supervisory Board, stated: "The Supervisory Board is excited to add the significant executive management, clinical and technical expertise that Andrew brings to the Executive Board of Epigenomics AG. Dr. Lukowiak has continually demonstrated the ability to deliver innovative tests through the FDA and the reimbursement process that have then led to commercial success. His breadth and depth of experience is ideally suited for Epigenomics to successfully execute the strategic plan for Epi proColon "Next-Gen"."
"I am excited to join the Epigenomics team and execute the plan for Epi proColon Next-Gen"," said Dr. Lukowiak. "Epigenomics’ "Next-Gen" blood-based cancer test has the potential to significantly improve colon cancer screening rates and save lives. The company’s leadership and innovation in liquid biopsy is an ideal platform to deliver an easy-to-use Real-time PCR based solution for hospital-based laboratories."